Document Detail

Trimetazidine shortens QTc interval in patients with ischemic heart failure.
MedLine Citation:
PMID:  19966175     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Trimetazidine improves functional class and left ventricular function in patients with heart failure; however, its potential impact on QTc interval remains undefined. We analyzed the effects of trimetazidine on QTc interval in patients with ischemic heart failure. METHODS: A prospective trial included 42 patients with ischemic heart failure (New York Heart Association [NYHA] 2 or 3) and reduced left ventricular ejection fraction (<55%), who were randomly allocated to conventional therapy plus trimetazidine in a modulated release formulation (35 mg twice daily; 22 patients) or conventional therapy alone (20 patients; controls). We measured QTc interval at baseline and after 1 month. RESULTS: At baseline, QTc interval duration was similar in both groups (443 +/- 41 milliseconds in trimetazidine group vs 446 +/- 27 milliseconds in controls, P = .62). After 1 month, QTc interval decreased in the trimetazidine group (404 +/- 36 milliseconds, P = .0002) but not in controls (452 +/- 25 milliseconds, P = .74). QTc interval shortening with trimetazidine was more pronounced in patients with prolonged (>440 milliseconds) baseline QTc interval (-45 +/- 38 milliseconds) than in patients with normal QTc interval (-19 +/- 19 milliseconds P = .04). Significant QTc interval shortening (>20 milliseconds) was present in 14 of 22 patients (64%) in trimetazidine group compared to 3 of 20 (15%) patients in control group (P = .002). CONCLUSIONS: Trimetazidine therapy is associated with QTc interval shortening in patients with ischemic heart failure.
Gregor Zemljic; Matjaz Bunc; Bojan Vrtovec
Related Documents :
1687925 - The effect of beta-adrenergic blockade in dilated cardiomyopathy--a questionnaire study...
19010175 - Analysis of heart rate turbulence in advanced heart failure and heart transplantation p...
16216975 - Effects of heat stress on thermoregulatory responses in congestive heart failure patients.
1269165 - Assessment by continuous cardiac monitoring of minimum duration of preoperative propran...
6615935 - Neurological and neuropsychological studies of patients with obsessive-compulsive disor...
14976595 - Low antibody levels against cell wall-attached proteins of streptococcus pyogenes predi...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2009-12-04
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  15     ISSN:  1940-4034     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-05     Completed Date:  2010-04-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  31-6     Citation Subset:  IM    
Advanced Heart Failure and Transplantation Center, Division of Cardiology, Ljubljana University Medical Center, Ljubljana, Slovenia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Electrocardiogram Pattern*
Heart Failure / drug therapy*,  physiopathology*
Middle Aged
Myocardial Ischemia / drug therapy*,  physiopathology*
Regression Analysis
Trimetazidine / pharmacology*
Vasodilator Agents / pharmacology*
Ventricular Function, Left / drug effects
Reg. No./Substance:
0/Vasodilator Agents; 5011-34-7/Trimetazidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Net flux of amino acids across the portal-drained viscera and liver of the ewe during abomasal infus...
Next Document:  Incidence of Appropriate Cardioverter-Defibrillator Shocks and Mortality in Patients With Heart Fail...